4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
AnaptysBio, Inc. (ANAB) operates in the Biotechnology industry and is headquartered in San Diego, United States with about 104 employees. Its market capitalization is roughly $2 billion. In the fiscal year ended 2025-12-31, ANAB reported $235M in revenue and ($13M) in net income.
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States.
Interactive charts & full statements → Open the ANAB valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | $235M | $91M | $17M | $10M |
| Operating Income (EBIT) | $48M | ($115M) | ($157M) | ($115M) |
| Net Income | ($13M) | ($145M) | ($164M) | ($129M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $26M | $108M | $76M | $22M | $28M | — |
| Operating Income (EBIT) | ($35M) | $67M | $35M | ($26M) | ($28M) | — |
| Net Income | ($53M) | $50M | $15M | ($39M) | ($39M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $364M | $484M | $452M | $610M | — |
| Total Liabilities | $327M | $413M | $364M | $348M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ANAB viewer.
About TickerBase · Data methodology & sources